title: Killed but metabolically active vaccines.
abstract: Beginning in the 20th century and continuing into the new millennia, vaccines against numerous diseases have had an unquestioned principal role of both enhancing the quality of life and increasing life expectancy (Rappuoli R, Mandl CW, Black S, De Gregorio E: Vaccines for the twenty-first century society. Nat Rev Immunol 2011, 11:865-872). Despite this success and the development of sophisticated new vaccine technologies, there remain multiple infectious diseases including tuberculosis, malaria and AIDS that await an effective prophylactic vaccine. In addition, there have been recent clinical successes among individuals with cancer using vaccine treatment strategies-so-called therapeutic vaccines-that stimulate tumor specific immunity and increase survival (Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al.: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med 2010, 363:411-422). Here we summarize a new class of vaccines termed Killed But Metabolically Active (KBMA). KBMA vaccines are whole pathogenic or attenuated organisms killed through photochemical inactivation and cannot cause disease, yet retain sufficient metabolic activity to initiate a potent immune response. KBMA vaccines have two broad applications. First, recombinant KBMA vaccines encoding selected antigens relevant to infectious disease or cancer can be used to elicit a desired immune response. In the second application, KBMA vaccines can be derived from attenuated forms of a targeted pathogen, allowing for the presentation of the entire antigenic repertoire to the immune system, of particular importance when the correlates of protection are unknown.
authors.affiliation: Aduro BioTech, Inc., Berkeley, CA 94710, United States. tdubensky@adurobiotech.com
authors.forename: Thomas W
authors.initials: TW
authors.lastname: Dubensky
authors.forename: Justin
authors.initials: J
authors.lastname: Skoble
authors.forename: Peter
authors.initials: P
authors.lastname: Lauer
authors.forename: Dirk G
authors.initials: DG
authors.lastname: Brockstedt
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology; D002986:Clinical Trials as Topic; D004260:DNA Repair; D005363:Ficusin; D006801:Humans; D007891:Leishmania / Q000276:immunology; D008089:Listeria monocytogenes / Q000235:genetics / Q000276:immunology; D014466:Ultraviolet Rays; D014613:Vaccines, Attenuated / Q000276:immunology; D015164:Vaccines, Inactivated / Q000276:immunology* / Q000528:radiation effects / Q000600:supply & distribution; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated; D014614:Vaccines, Synthetic; D005363:Ficusin